Welcome, Introduction, Polling, and Presurvey Questions
Advances in Current Management of Cervical Cancers
- Cervix cancer overview
- HPV Infection and tumorigenesis
- HPV vaccination and preventative measures
- Current treatments algorithms for advanced/metastatic cervix cancer
- Novel therapies in development
- Antibody–drug conjugates
- Case-based discussion of current data
Audience Q&A Session
Date / Time
Linda R. Duska, MD, MPH
Department of OB GYN/Gynecologic Oncology
University of Virginia School of Medicine
Ritu Salani, MD, MBA
Professor and Division Director
OB/GYN and Gynecologic Oncology
University of California, Los Angeles
Los Angeles, California
Shannon N. Westin, MD, MPH
Division of Surgery
Department of Gynecologic Oncology and Reproductive Medicine
University of Texas MD Anderson Cancer Center
The goal of this program is to improve patient care by increasing healthcare professional knowledge, competence, and performance in applying new data and managing adverse events of new therapies in the increasingly complex treatment landscape in advanced cervical cancer.
This program is intended for oncologists, oncology nurses, nurse practitioners, pharmacists, and other healthcare professionals involved in the care and management of patients with advanced cervical cancer.
Upon completion of this activity, participants should be able to:
- Describe the mechanism of action of novel therapies used to treat recurrent/metastatic cervical cancer.
- Plan therapy for patients with metastatic cervical cancer based on available data, expert recommendations, and consideration of optimal treatment sequencing
- Collaborate with gynecologic oncology and multidisciplinary colleagues to prevent and―if necessary―manage treatment-related symptoms from recently approved targeted agents and ICI-based therapies
Joint Accreditation Statement
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Physician Continuing Medical Education
Designation of Credit
CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Continuing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.
Continuing Pharmacy Education
CCO designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-22-148-L01-P
Type of Activity: Application
Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.
Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.